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1. INTRODUCTION 
Breast cancer is one disease, the management of which keeps evolving and 
continues to baffle the clinician from ages. The surge for refinement in treatment 
modalities of breast cancer is ever growing and it is one of the most extensively studied 
diseases. Being the commonest cancer among women in the developed world, 
tremendous amount of research has gone into understanding the biology of this disease 
and novel treatment approaches are being investigated across the world.  
Breast cancer is a disease with potential for systemic spread with high risk of 
local recurrence. Essentially, the treatment of invasive breast cancer has surgery and 
radiation therapy as the modes for local control of the disease and chemotherapy for 
addressing the systemic micrometastasis. Radiation therapy is inherent in the setting of 
breast conservation therapy. Modified radical mastectomy is followed up with radiation 
therapy to the chest wall, supraclavicular or the axillary region according to specific 
indications. 
Treatment of breast cancer spans across six to eight months and radiation therapy 
contributes to about five weeks. Necessity is the mother of invention. The ever-growing 
number of breast cancer patients requiring either chest wall or whole breast irradiation in 
the United Kingdom, put many radiotherapy centres under pressure. To reduce the 
workload on machines, many centres started using shorter radiotherapy schedules with 
larger doses per fraction. Case series and cohort studies initially reported that these 
shorter schedules were acceptable in terms of both acute reactions and local control.   
Evolving radiobiological concepts has opened gates to research aimed at reducing the 
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treatment duration from five weeks to three weeks have proved that it is feasible in terms 
of tumour control and safety. The concept of hypofractionated radiotherapy was initially 
applied to breast cancer as early as 1986((1)) in the United Kingdom. Since then several 
randomized studies have been conducted on this shorter fractionation regimens, the 
landmark trials being the START A and START B trials. 
The concept of hypofractionated radiotherapy has not become the standard of care 
in our country. The shorter treatment schedule is supposed to reduce the burden on 
treatment units and indirectly reduce the cost of treatment. Indian breast cancer scenario 
will definitely benefit from this well established treatment regimen.   
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2. REVIEW OF LITERATURE 
2.1 INCIDENCE AND PREVALENCE 
Cancer is one of the leading diseases in the world, both in the developed and the 
developing countries. Improved health system, the consequent increase in longevity and 
addictive habits like smoking, alcoholism, tobacco chewing and life style changes has 
contributed to the increased incidence of cancer.  About 7.6 million cancer related deaths 
have been estimated to have occurred in 2008(Figure 2.1). The major proportion of these 
deaths (64%) occurred in the developing countries. Breast cancer contributes to 23% of 
the cancers diagnosed and is the second most common malignancy worldwide, lung 
cancer being the most common (2). Cancer breast continues to be the most common 
cause of cancer related deaths among women. It accounts for 14% of the cancer deaths. 
In the United States, it was found that after consistently rising for years, the incidence of 
breast cancer has started to decrease in the last decade which could partly be due to the 
decreasing trend of using hormone replacement therapy.  Incidence of breast cancer in 
India shows a variable pattern within the country, with significant differences noted 
between metropolitan cities and rural India.   
The incidence rates are 33, 24 and 7.5 per 100000 in metropolitan cities, urban 
areas and rural India respectively. Even though breast cancer is the second most common 
cancer (cancer cervix being the most common) in India as a whole, data from a 
nationwide study-Atlas of Cancer in India, shows that in metropolitan cities breast cancer 
is the most common cancer(3). 
The Indian cancer registries have shown an increase of about 0.5% per year 
incidence between the years 1991-2005 and it varies greatly between the urban and rural 
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areas of India. The Mumbai cancer registry shows an increase of 1.1% per annum over a 
30 year period from 1975-2005(4). National Cancer Registry Program (2006- 2008) 
reported an incidence of 33 and 32.1 per 100000 population in Mumbai and Chennai, 
while Pune and Bhopal had an incidence of 24.4 and 25.5 per 100000, and the rural India 
had an incidence of 7.4 per 100000 (NCRP, unpublished data). 
 
 
Figure 2.1: Worldwide Cancer Incidence 
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Figure 2.1: Common sites of cancers in female: Extrapolation to population of India, 2004 (ICMR) 
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2.2 ETIOLOGY 
Breast cancer is a result of a series of events, both genetic and epigenetic, which 
finally culminates in dysregulation of cell growth, apoptosis and leads to development of 
invasive nature. The causes of these events are not clear, but studies have shown that 
lifestyle, environmental factors and germ line genetic factors predisposes one to breast 
cancer. Female sex is the strongest risk factor for developing breast cancer and only 
about 1% of all new breast cancer occur in men(5).  The second most important risk 
factor is the age, as 95% of all new cases occur in women aged 40 years and above. 
Above 40 years, the annual risk of developing breast cancer increases exponentially until 
menopause, after which the risk lowers considerably(6). Estrogen exposure is a known 
risk factor for developing breast cancer. Situations where this excess estrogen exposure 
occurs are early menarche, late menopause, nulliparity and older age at the time of first 
child birth. Post menopausal hormone replacement therapy with Estrogen also has shown 
to increase the chances of one developing breast cancer. The annual relative risk of 
developing breast cancer increases by 2.3% per each year of hormonal therapy taken(7).  
Another recent study reported that combined estrogen and progesterone hormonal therapy 
is associated with an increase in relative risk by 8% when compared with non users, 
whereas the use of estrogen alone increases the relative risk only by 1%(8).  A large 
Swedish study reported that the risk of breast cancer increases approximately by 13% for 
every 5 years increase in the age of first child birth(9). Alcohol consumption has been 
found to be associated with breast cancer risk(10). There is no strong evidence for any 
association between dietary fat and breast cancer risk(11).  Regular exercise has been 
proved to reduce the risk of developing breast cancer(12,13). 
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   Genetic events leading to breast cancer are more often sporadic than germ line 
mutations. Approximately 20 to 25% of patients with breast cancer have family history of 
breast cancer. The two most common tumor suppressor genes which undergo mutation 
are the BRCA 1 and BRCA 2.  Female carriers of germ line BRCA1 mutation have a life 
time risk of breast cancer exceeding 80% and of ovarian cancer close to 60%(14). BRCA 
2 mutant also carry a similar risk of development of breast cancer and a higher chance of 
developing ovarian cancer. Growth promoting proto oncogenes can become abnormal 
which is commonly seen in locally advanced breast cancer. Over expression of the proto 
oncogene Her2/neu has been associated with increased proliferative capacity and higher 
metastatic potential.  
2.3 BIOLOGIC CHARACTERISTICS 
Breast cancer has been grouped into several molecular subtypes based on DNA 
microarray expression profiles. These molecular subgroups correspond with different 
prognostic groups and predict the aggressiveness of the disease. The four molecular 
subtypes are luminal A, luminal B, Her2 tumors and basal-like type. Luminal A tumors 
include most ER positive, PR positive and Her2/ neu negative tumors. Luminal B tumors 
are ER positive, PR positive and Her 2 neu positive. Her2 tumors are ER negative, PR 
negative and Her2/neu negative. Basal-like subtype is triple negative disease. Luminal A 
type of tumors is generally associated with the best prognosis and predicts the response to 
hormonal therapy. Basilar type tends to be more chemoresponsive, but is associated with 
aggressive biology and poor prognosis. 
13 
 
 
 
 
 
 
Figure 2.2: Levels of axillary nodes 
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2.4 ANATOMY 
The breast is situated on the Pectoralis Major muscle and cranio-caudally extends 
between the second and the sixth ribs and between the sternal edge medially and the mid 
axillary line laterally. Skin, subcutaneous tissue and the breast tissue constitutes the 
breast. Breast tissue is composed of epithelial and stromal components. The breast tissue 
is supported by fibrous septae called Cooper’s ligaments and connective tissue which 
harbours the blood vessels, lymphatics and nerves. The fascia of the Pectoralis fascia 
muscle forms the deep boundary of the breast. Lobules and ducts form the microscopic 
structural background of the breast. The interface between the lobule and duct is a 
common site where breast cancer develops(15). The rich lymphatic drainage of the breast 
primarily drains into the lymph nodes of axilla, internal mammary chain and the 
supraclavicular region. 
Drainage can also occur into the intramammary nodes and the interpectoral 
Rotter’s nodes. Axillary nodes are divided into three levels with respect to their anatomic 
location in relation to Pectoralis Minor muscle (Figure 2. 3). Those nodes which are 
inferolateral to the lateral border of the Pectoralis Minor are called the Level I axillary 
nodes. Level II nodes lie beneath the Pectoralis Minor muscle and those nodes which lie 
superomedial to the Pectoralis Minor muscle are called the Level III nodes.  When the 
internal mammary chain gets involved usually the lymph nodes lie in the second, third 
and fourth intercostals spaces. The incidence of metastasis to the internal mammary 
nodes depends on the number of axillary nodes involved and the anatomic location of the 
tumour within the breast. Medial and central quadrant tumours with 4 or more positive 
axillary nodes had the highest rate (43%) of IMC involvement according to a study from 
China(16) .  Risk of supraclavicular nodal involvement is dependent on the number of 
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positive axillary nodes. Around 15% of patients with four or more positive axillary nodes 
will develop supraclavicular recurrence if this region is left untreated(17).    
2.5 DIAGNOSIS 
In the Indian scenario, most of our patients present to the clinic many months 
after being aware of a breast lump, mostly due to the social stigma associated with it. The 
clinical diagnosis of breast cancer is straight forward in most cases when patients present 
with a hard lump in the breast. Routine screening mammogram may pick up micro-
calcifications leading to the diagnosis of cancer. History and physical examination is the 
most important step towards diagnosis. Ultrasonogram of the breast and axilla is the 
preferred imaging in young premenopausal women. Mammogram is the recommended 
imaging for older women with dense parenchyma. These imaging modalities also provide 
information regarding the status of the axillary nodes and the contralateral breast.  If any 
abnormality is picked up in the physical examination or imaging, then tissue needs to be 
obtained to rule out cancer. Per cutaneous core biopsy is the recommended procedure. 
Fine needle aspiration from the breast lump will aid in confirming the diagnosis without 
much delay, but further characterization and immunohistochemical tests will not be 
feasible. In a case where the patient is scheduled for an upfront mastectomy, FNAC 
would suffice as the surgical histopathology will be soon available. When a patient 
requires downstaging of the disease with neoadjuvant chemotherapy prior to surgery, a 
trucut biopsy is a must prior to initiation of the chemotherapy. Ultrasound guided biopsy 
might be needed when the breast lump is small and difficult to palpate. When the patient 
does not have a palpable lump and has suspicious microcalcifications, a stereotactic 
biopsy is recommended. Bone scan is recommended for all patients with locally 
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advanced disease. Upto 3 % of patients with clinical stage III disease has abnormal bone 
scans .Once the diagnosis is established, further evaluation aims at staging the disease. 
Routine tests included in the metastatic work up include, chest X ray and ultrasonogram 
of the abdomen and pelvis.  
2.6 HISTOPATHOLOGICAL CLASSIFICATION OF BREAST 
TUMOURS(AJCC) 
In situ Carcinomas 
Not otherwise specified 
Intraductal (insitu) 
Paget’s disease and intraductal 
Invasive carcinomas 
Not otherwise specified 
Ductal, Inflammatory, Medullary, Medullary with lymphoid stroma, Mucinous, Papillary 
(predominantly micro papillary pattern), Tubular, Lobular, Paget’s disease, 
Undifferentiated, Squamous cell, Adenoid cystic, Secretory, Cribriform 
2.7 STAGING 
American Joint Committee for Cancer staging seventh edition (2010) is used for 
staging purpose.  
Primary Tumor (T) 
 
 
Tx 
 
Primary tumor cannot be assessed 
 
T0 
 
No evidence of primary tumor 
 
Tis 
 
Carcinoma in situ 
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Tis (DCIS) 
 
Ductal Carcinoma In Situ 
 
Tis (LCIS) 
 
Lobular Carcinoma In Situ 
 
Tis 
(Paget’s) 
 
Paget’s disease of the nipple with no tumor 
 
T1 
 
≤2cm in greatest dimension 
 
T1mi 
 
Microinvasion 0.1cm or less in greatest dimension 
 
T1a 
 
Tumor >0.1cm but not more than 0.5cm in greatest dimension 
 
T1b 
 
Tumor >0.5cm but not more than 1cm in greatest dimension 
 
T1c 
 
Tumor >1cm but not more than 2cm in greatest dimension 
 
T2 
 
Tumor >2cm but not more than 5cm in greatest dimension 
 
T3 
 
Tumor more than 5cm in greatest dimension 
 
T4 
 
Tumor of any size with direct extension to a)chest wall or b) skin, only as described 
below 
 
T4a 
 
Extension to the chest wall, not including only Pectoralis muscle invasion 
 
T4b 
 
Edema (including peau d’orange) or ulceration of skin of the breast or satellite skin 
nodules confined to the same breast 
 
T4c 
 
Both(T4a and T4b) 
 
T4d 
 
Inflammatory carcinoma 
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Regional Lymph Nodes (N) 
 
 
Nx 
 
Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
 
N1 
 
Metastasis in movable ipsilateral Level I ,II axillary node(s) 
 
N2 
 
Metastasis in ipsilateral Level I, II node(s) that are clinically fixed or matted; 
or  in clinically detected ipsilateral internal mammary node in the absence of 
clinically evident axillary lymph node metastasis  
 
N2a 
 
Metastasis in axillary lymph node(s) fixed to one another(matted) or to other 
structures 
 
N2b 
 
Metastasis only in clinically detected internal mammary lymph node(s) and 
in the absence of clinically detected axillary lymph node metastasis  
 
N3 
 
Metastasis in ipsilateral infraclavicular lymph node(s) with or without level I 
,II axillary lymph node involvement or in clinically detected internal 
mammary lymph node(s) with clinically evident level I, II axillary lymph 
node metastasis; or metastasis in ipsilateral supraclavicular lymph node(s) 
with or without axillary or internal mammary lymph node involvement 
 
N3a 
 
 
Metastasis in infraclavicular lymph node(s) 
 
 
N3b 
 
Metastasis in internal mammary and axillary lymph nodes 
 
N3c 
 
Metastasis in supraclavicular lymph node(s) 
 
 
M0 
 
No metastasis 
 
M1 
 
Distant metastasis 
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STAGE GROUPING   
 
 
Stage 0 
 
Tis 
 
N0 
 
M0 
 
Stage I A 
 
T1* 
 
N0 
 
M0 
 
Stage I B 
 
T0, T1 
 
N1mi 
 
M0 
 
Stage II A 
 
T0, T1* 
 
N1 
 
M0 
 
 
 
T2 
 
N0 
 
M0 
 
Stage II B 
 
T2 
 
N1 
 
M0 
  
T3 
 
N0 
 
M0 
 
Stage III A 
 
T0, T1*, T2 
 
N2 
 
M0 
 
 
 
T3 
 
N1, N2 
 
M0 
 
Stage III B 
 
T4 
 
N0, N1, N2 
 
M0 
 
Stage III C  
 
Any T 
 
N3 
 
M0 
 
Stage IV 
 
Any T 
 
Any N 
 
M1 
 
*T1 includes T1mi 
 
The categories M1 and pM1 may be further specified according to the following notation: 
Pulmonary          PUL     Osseous             OSS 
Hepatic               HEP    Brain                 BRA 
Lymph nodes     LYM   Bone marrow    MAR 
Pleura                 PLE    Peritoneum        PER 
Adrenals            ADR    Skin                   SKI 
Others                OTH 
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pTNM Pathological Classification 
pT –Primary Tumor 
The pathological classification requires the examination of the primary carcinoma 
with no gross tumour at the margins of resection. A case can be classified pT if there is 
only microscopic tumour in a margin. 
The pT categories correspond to the T categories. 
When classifying p T the tumour size is a measurement of the invasive component. If 
there is a large in situ component (4cm) and a small invasive component (eg: 0.5 cm), the 
tumour is coded pT1a. 
pN- Regional Lymph Nodes 
The pathological classification requires the resection and examination of atleast 
the low axillary lymph nodes (Level I). Such a resection will ordinarily include 6 or more 
lymph nodes. If the lymph nodes are negative, but the number ordinarily examined is not 
met, classify as pN0. 
 
       pNx 
Regional lymph nodes cannot be assessed (e.g. previously removed, or not 
removed for pathological study) 
      pN0 No regional lymph node metastasis
*
 
 
Note *Isolated tumour cell clusters (ITC) are single tumour cells or small clusters of cells 
not more than 0.2 mm in greatest extent that can be detected by routine H and E stains or 
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immunohistochemistry. An additional criterion has been proposed to include a cluster of 
fewer than 200 cells in a single histological cross-section. Nodes containing only ITCs 
are excluded from the total number of positive node count for purposes of N 
classification and should be included in the total number of nodes evaluated.  
 
 
pN1 
Micrometastasis; or metastasis in 1-3 axillary ipsilateral lymph nodes; and/or in 
internal mammary nodes with metastasis detected by sentinel lymph node biopsy 
but clinically not detected. 
pN1mi Micrometastasis (larger than 0.2 mm and/or more than 200 cells, but none larger 
than 2.0 mm) 
pN1a 
 
Metastasis in 1-3 axillary node(s), including at least 1 larger than 2 mm in greatest 
dimension. 
pN1b Internal mammary lymph nodes with microscopic or macroscopic metastasis 
detected by sentinel lymph node biopsy but not clinically detected. 
 
pN1c 
Metastasis in 1-3 axillary lymph nodes and internal mammary lymph nodes with 
microscopic and macroscopic metastasis detected by sentinel lymph node biopsy 
but not detected clinically. 
 
 
pN2 
Metastasis in 4-9 ipsilateral axillary lymph nodes, or in clinically detected 
ipsilateral internal mammary lymph node(s) in the absence of axillary lymph node 
metastasis  
 
pN2a 
Metastasis in 4-9 axillary lymph nodes, including at least one that is larger than 
2mm 
 
pN2b 
Metastasis in clinically detected internal mammary lymph node(s), in the absence 
of axillary lymph node metastasis 
pN3a Metastasis in 10 or more axillary lymph nodes (at least one larger than 2mm) or 
metastasis in infraclavicular lymph nodes. 
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pN3b Metastasis in clinically detected internal ipsilateral lymph node(s) in the presence 
of positive axillary lymph node(s);or metastasis in more than 3 axillary lymph 
nodes and in internal mammary lymph nodes with microscopic or macroscopic 
metastasis detected by sentinel lymph node biopsy but not clinically detected. 
pN3c Metastasis in ipsilateral supraclavicular lymph node(s) 
 
 
 
2.8 OVERVIEW OF CURRENT TREATMENT GUIDELINES IN BREAST 
CANCER 
 
Breast cancer treatment is evolving constantly due to the alarmingly high 
incidence of this disease recently. Breast cancer can be broadly classified as early breast 
cancer (EBC), locally advanced (LABC) and metastatic breast cancer (MBC). Early 
breast cancer includes Stages I, II and III A. Stages III B and III C are grouped into the 
category of locally advanced breast cancer. Treatment of breast cancer is based on these 
broad categories. Surgery is the mainstay of treatment for early breast cancer. The trends 
in surgical management are also evolving and more and more patients who are eligible 
are opting to have breast conservation surgery.  Modified Radical Mastectomy still 
continues to be widely used in India.  
Modified radical mastectomy is removal of breast with level I/II axillary clearance. 
2.9 SURGERY 
Surgery is the principal loco regional treatment for any patient with early breast 
cancer. In case the disease is inoperable at presentation, the patient is re assessed for 
operability after a course of neoadjuvant chemotherapy which helps in downstaging the 
disease. Surgery addresses both the primary tumour and the axillary nodes. The primary 
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tumour is managed by either a mastectomy or lumpectomy and the axillary nodes are 
managed by a sentinel node biopsy or axillary dissection. The various surgical procedures 
do have an impact on the adjuvant oncological management.  
Radical Mastectomy, Extended Radical Mastectomy, Modified Radical 
Mastectomy, Simple mastectomy, Skin sparing and Nipple sparing Mastectomy are all 
procedures that remove a considerable bulk of the breast parenchyma along with the 
primary tumour.  The term Breast Conserving surgery can be collectively applied for 
procedures like lumpectomy, partial mastectomy, tylectomy and quadrantectomy. Simple 
mastectomy removes the breast tissue with the tumour alone and the axilla is not 
addressed. Radical mastectomy involves removal of the breast plus the Pectoralis major 
muscle and a level I/II axillary dissection. Modified radical mastectomy removes the 
breast with level I/II axillary clearance. When immediate re construction is considered, 
the preferred surgical procedure is Skin sparing mastectomy, which is nothing but a total 
or radical mastectomy where in the surgeon leaves a significant component of the native 
skin of the breast to optimize the aesthetic outcome of a reconstruction.  
In general there is a trend towards less radical surgery from radical mastectomy to breast 
conservation surgery(18). There is no significant difference between breast conservation 
therapy and mastectomy in terms of overall survival rates, which is 45-90 % at five 
years(19).Breast conservation and mastectomy were recognized by the national institute 
of health to have equivalent medical outcome in a consensus development conference 
held in 1990 and recommended BCT for most of the women with early breast cancer(20–
22). A study from the United States reported that even though breast conservation was an 
option for about 75%  of patients with early breast cancer, only 20-50% of these patients 
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opted to conserve their breasts(23). Fear of recurrence of cancer was the most important 
factor which made these patients opt mastectomy(23). Patients who are eligible for 
surgery are assessed for suitability of breast conservation along with discussion with the 
patient regarding the options.  
The following absolute contraindications need to be kept in mind while offering 
breast conservation therapy: 
1. Pregnancy, especially first and second trimester. 
2. Diffuse malignant appearing micro-calcifications 
3. Multi-centric breast cancer 
4. Previous history of irradiation of the breast region that would lead to an 
unacceptable high total dose delivered when post operative whole breast RT is 
given. 
5. Persistent positive margins after multiple surgical attempts. 
Relative contraindications include 
1. History of collagen vascular disease 
2. Tumour size large tumour in a small breast 
3. Large or pendulous breast can be a relative contraindication as reproducibility and 
immobilization will be difficult.  
Mastectomy is indicated in cases where breast conservation is contraindicated or 
when the patient opts to have the entire breast removed. 
Following the surgery, further adjuvant treatment is based on the 
histopathological examination, the initial clinical stage of the disease and the hormone 
receptor status. Human epidermal growth factor receptor2 (Her2/neu) status is helpful in 
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predicting response to targeted therapy. Radiation therapy, chemotherapy, hormonal 
therapy and targeted therapy are the options for adjuvant treatment. 
 
In India 30-35% of breast cancers are locally advanced at the time of 
diagnosis(24). Ignorance and fear of being diagnosed to have cancer, prevents many 
women from the rural areas, from seeking timely medical attention. This, along with poor 
screening strategies might be the explanation for such high number of locally advanced 
breast cancers in our country.   
 Patients, who present with locally advanced disease, have a course of 
neoadjuvant chemotherapy prior to surgery. Chemotherapy reduces the tumor size and 
makes it operable and at the same time provides systemic treatment.  
2.10 POST MASTECTOMY RADIATION THERAPY 
Results of several randomized studies showed that, in the absence of radiation 
therapy following mastectomy, there is a significant risk of locoregional failure(25,26). 
Approximately 25–40% of node positive patients and 15-40% of node negative patients 
may develop loco regional recurrence in the absence of radiotherapy. Locoregional 
recurrence most commonly develops in the chest wall, followed by axilla and the 
supraclavicular region. Recurrence on the chest wall can be distressing for the patients as 
it can ulcerate or fungate.  Supraclavicular recurrence can cause neuropathy and 
significantly hamper the quality of life. Disease recurrence in axilla can lead to 
lymphoedema.    
There is strong evidence to show that post mastectomy radiation therapy reduces 
the rate of loco regional failures in those patients who have a high risk of local failure. It 
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did not take much longer to prove that adjuvant radiotherapy not only improved 
locoregional control, but survival also. The British Columbia Cancer Agency(27) and the 
Danish Breast Cancer Cooperative group(28) conducted two randomized controlled trials, 
which were initially published in 1997  and was updated in 2005 and 2006. These were 
the first trials which demonstrated a survival advantage with radiation therapy over and 
above the locoregional control. Danish 82b trial compared radiation therapy plus CMF 
(Cyclophosphamide, Methotrexate and 5 Fluorouracil) with CMF alone in premenopausal 
women. At a median follow up of 10 years, the study reported statistically significant 
improvement in rates of local recurrence(32% vs. 9%), disease free survival(34% vs. 48 
%) and overall survival(45% vs. 54%) in the combination group(29).  Four or more 
positive axillary nodes, T3 tumours with positive axillary node and operable Stage III 
tumours are the indications for post mastectomy radiation therapy. Downstaging achieved 
by neoadjuvant chemotherapy will not alter the plan for adjuvant radiotherapy if it was 
indicated at presentation. Adequate coverage of the chest wall is mandatory in all these 
patients. Axillary irradiation is not routinely given to patients who have undergone a 
complete axillary dissection. The risk of lymphedema significantly rises when axillary 
dissection is combined with axillary irradiation. Only those patients who have evidence 
of extra nodal tumour deposits are treated with axillary irradiation.  Supraclavicular 
failure rate is high in patients with four or more positive axillary nodes and 
supraclavicular region is included along with chest wall irradiation(30).  There is 
insufficient data to offer supraclavicular radiation therapy to those patients with 1 to 3 
positive axillary lymph nodes. Traditionally the dose prescribed for post mastectomy 
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radiation therapy is 50Gy in 25 fractions, 2Gy per fraction, five days a week. The total 
treatment duration was around five weeks. 
2.10.1 THREE DIMENSIONAL CONFORMAL RADIOTHERAPY 
The aim of radiotherapy is to deliver a homogenous dose to the target and at the 
same time keep the normal tissue complications to the minimum(31). Conventional 
radiotherapy with simple beam arrangements partially achieves this goal, but this may 
lead to unnecessary irradiation of large volumes of normal tissues. The shape of the chest 
wall can be highly variable and the close proximity to the lung and the heart, further 
warrants accurate dose delivery to the target. Two dimensional planning has the 
limitation that it cannot represent the prescribed dose delivered to a specified target 
volume and the volume of normal tissue irradiated is also ambiguous. Three dimensional 
conformal radiotherapy uses CT images to accurately delineate the target volume and the 
organs at risk. Dose Volume Histograms (DVH) are generated using three dimensional 
treatment planning system, which gives an estimate of the dose delivered to the target and 
the normal tissue. 3DCRT technique for chest wall when compared to two dimensional 
technique was found to reduce the ipsilateral mean lung dose by 24.6%. The V20 was also 
reduced using 3DCRT (22.2% vs. 30%). The mean dose delivered to the contralateral 
breast was also significantly lower in the conformal technique (8.2 % of the prescribed 
dose to target vs. 10.4%). For left sided breast cancer, it was seen that the mean dose to 
the heart could be reduced by 48.6 % using 3DCRT. The PTV coverage was also better 
with 3DCRT when compared to two dimensional treatment. Thus 3DCRT technique has 
the advantage that it is able to generate significantly better homogeneity index for the 
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PTV with a significant reduction in the mean doses to the ipsilateral lung and heart in left 
sided tumours(32). 
2.10.2 RATIONALE FOR THE STANDARD FRACTIONATION 
Fractionation of radiation dose provides better control of the tumor at a given 
level of normal tissue toxicity. The international standard 2Gy per fraction regimens are 
based on data from squamous cell carcinomas of the head and neck region, cervix and 
bronchi, which proved that these tumours are less sensitive to the dose per fraction than 
the late responding healthy tissues. Using doses more than 2Gy per fraction in these types 
of tumours would result in higher rate of late complications than tumour control.  In post 
mastectomy radiation therapy the effective dose to be delivered is chosen in such a way 
that there is a balance between control of recurrence and side effects on the normal 
healthy tissue. 
The standard fractionation in post mastectomy radiotherapy is based on the fact 
that the high total dose delivered in small fractions of 2Gy would offer maximum tumour 
control with minimum damage to normal tissue. This is based on the hypothesis that 
breast adenocarcinomas have similar sensitivity to fraction size as the squamous cell 
carcinomas. 
2.11 EVOLUTION OF HYPOFRACTIONATION IN BREAST CANCER 
Retrospective analysis of the enormous data available on breast cancer led to a 
hypothesis that breast cancer might be much more sensitive to fraction size than many 
other cancers. Sensitivity to fraction size in radiobiological terms can be quantified by the 
value α/β, which is a variable, derived from the commonly used LQ (Linear Quadratic) 
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model of fractionation.  α and β are coefficients that are typical of the tissue under 
consideration. The response to fraction size is not linear but fits into the linear-quadratic 
function in which clinical response is proportional to αD + βD2, where D is the fraction 
size. Effect of fraction size is measured by the degree of tissue damage on normal tissue 
and tumour recurrence rates for malignant tumours. The ratio of α and β is expressed in 
Gy. The lower the ratio the greater will be the effect of change in fraction size on normal 
tissue and malignant tumour. Head and neck carcinomas have α/β value of 10Gy and they 
are less sensitive to the individual fraction size. This is the rationale behind treating them 
with small fractions of 2Gy each to a high total dose of 60-66Gy, keeping normal tissue 
late effects minimum and maximum tumour control. If the hypothesis is true it means that 
breast adenocarcinoma has α/β value of 3-5Gy (33), which in turn means that these 
tumours are very sensitive to change in fraction size. Hence increasing dose per fraction 
above 2Gy would provide better tumour control. Initial studies attempted to increase the 
dose per fraction above 2Gy, without reducing the total dose and had to confront 
unacceptable rates of late adverse effects.  
The Oncologists in United Kingdom has been using the hypofractionated (three 
weeks) regimen for decades due to the ever increasing demand for radiotherapy in breast 
cancer patients. The only evidence based which these schedules were practiced came 
from small case series and cohorts. There was always a pressure on radiotherapy 
equipments and staff due to the high patient load. The centres empirically using the three 
weeks regimen were facing the pressure of considering the internationally popular five 
weeks regimen (50Gy in 25 fractions).  
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The two trials which provided data supporting the higher sensitivity of breast 
cancer are the UK Pilot trial which began in 1986 and the Canadian trial which began in 
1993. The UK Pilot trial used three arms, 50Gy in 25 fractions, 39Gy in 13 fractions and 
42.9Gy in 13 fractions all over a total duration of five weeks. The Canadian trial 
compared 42.5Gy in 16 fractions with the standard schedule. There was a wide range of 
variation in post mastectomy dose prescription within United Kingdom and hence to 
address this issue and the issue of workload, the UK Coordinating Committee on Cancer 
Research proposed a trial of standardization of breast radiotherapy. The aim was to study 
the effect of increasing the fraction size above 2Gy, on normal tissues, tumour control, 
quality of life and its financial implications.  
The Standardisation of Breast Radiotherapy (START) trials (A and B) began in 
1998. The trials recruited patients between 1999 and 2002 and the majority of patients 
were patients who had Breast conservation surgery (85%) and the rest were post 
mastectomy patients. START A compared the standard regimen with two other 
schedules, 41.6Gy and 39Gy in 13 fractions over five weeks. The START B trial 
compared the standard regimen with 40Gy in 15 fractions over three weeks. In 2010 
Cochrane review concluded that hypo-fractionation in breast cancer does not compromise 
efficacy or safety, but suggested that a longer follow up analysis was warranted. The ten 
year results of these two randomized controlled trials have been published in the Lancet 
Oncology in 2013. START A enrolled 2236 women and 139 local regional relapses 
occurred after a median follow up of 9.3 years. The ten year rates of locoregional relapse 
did not vary significantly among the study groups (6.3%, 7.4% and 8.8% in the 41.6Gy, 
50Gy and 39Gy groups respectively). The late effects like breast oedema, telangiectasia 
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and induration were significantly lower in the 39Gy group compared to the standard 
regimen. There was no significant difference in late effects between the 41.6Gy and 
50Gy arms. START B enrolled 2215 and the median follow up was 9.9 years. The ten 
year recurrence rate was similar in the 40Gy and 50Gy groups (4.3% and 5.5% 
respectively). The breast related side effects were significantly lower in the hypo-
fractionated arm compared to the standard 50Gy arm.  The other late effects which were 
assessed were symptomatic rib fracture, ischemic heart disease, symptomatic lung 
fibrosis and brachial plexopathy. The aforementioned late effects were very rare across 
all the study groups. In the START B trial there was not even one case of brachial 
plexopathy. The hypofractionated schedule (40Gy in 15 fractions) was found to be less 
damaging to the brachial plexus even under extreme assumptions regarding the 
sensitivity of the plexus. With regards to cardiac events, hypofractionation seems to 
protect the heart, even though ten years is not sufficient for assessing the cardiac 
morbidity.  
2.12 RADIATION TOXICITY 
The benefits of local control and overall survival provided by post mastectomy 
radiotherapy are associated with certain side effects.  The organs at risk in post 
mastectomy radiotherapy are the skin, subcutaneous tissue, ribs, lungs, heart, spinal cord 
and the opposite breast.  
Radiation induced damage can be influenced by certain patient and treatment 
related factors. Patient related factors like obesity being associated with higher risk of 
skin toxicity, co morbidities like diabetes mellitus, connective tissue disorders, cardiac 
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diseases and previous history of smoking also could have a detrimental effect on the 
toxicity profile. The treatment related factors like the energy chosen, the technique 
applied, dose prescribed and the treatment plan also can have an impact on the radiation 
induced damage.  
Toxicities can be classified as early and late effects. Early effects occur during the 
course of radiation therapy and upto six months post treatment. Late effects may occur 
from six months to years after the treatment. The acute side effect which is most 
commonly encountered is fatigue and irritation of skin. Fatigue is usually mild and does 
not affect the activities of daily living. Some form of radiation dermatitis occurs in most 
of the patients (90%) undergoing post mastectomy radiotherapy.  Radiation induces 
injury in the basal stem cells that are responsible for replenishing the superficial cornified 
layer of the epidermis(Figure 2.4). As a result of insult to the basal stem cells, eventually 
there is shedding of the cornified layer, which is termed as dry desquamation. 
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Figure 2.4: Layers of skin 
Radiation also causes dilatation of capillaries, increased vascular permeability, 
enhanced inflammatory response leading to erythema and oedema. Hyperpigmentation, 
epilation, loss of sebaceous glands and sweat glands are all part of radiation dermatitis, 
resulting in dry and pruritic skin. Migration of the melanocytes from the basal layer to the 
superficial layers causes hyper-pigmentation. Moist desquamation occurs with continued 
loss of basal layer which exposes the dermis. Moist desquamation can lead to frank 
ulceration.  
A study from Egypt, which looked into radiation dermatitis in conventional 
radiotherapy and hypo-fractionated radiotherapy in conserved breasts, reported that the 
peak incidence of severe skin reaction occurred during the fifth week of treatment in the 
conventional group and in the third week in the hypo-fractionated group. The study also 
reported that these reactions lasted for about three weeks in the conventional fractionation 
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group and for five weeks in the hypofractionated arm(34). The explanation for the early 
incidence of reactions in the hypofractionated group may be the dependence of timing 
and magnitude of inflammatory response on the rate of accumulation of dose. 
Inflammatory response does not clear up in hours like the sublethal damage does and 
hence the inflammatory response accumulates quickly(35). START B trial analysed 
patient self-assesments of five key normal tissue effects on the breast and chest. This 
analysis showed that rates of moderate/marked changes were lower in the 
hypofractionated radiotherapy group compared to the conventional arm(36). The various 
normal tissue effects like breast shrinkage, hardness, change in skin appearance, swelling 
in the area of affected breast, at five years were all consistently in favour of the 40Gy in 
15 fractions regimen. An unusually marked acute skin reaction occurred in 16 (0.7 %) 
patients in the START B trial. Of these 16 patients, 13 (1.2%) were in the conventional 
fractionation group and 3 (0.3 %) were from the study arm. Radiation dermatitis is graded 
based on the RTOG Acute Radiation morbidity scoring criteria(37). 
RTOG Acute Radiation Morbidity Scoring Criteria 
                Radiation pneumonitis typically occurs as a late effect and may present with 
low grade fever and dry cough. Interstitial inflammation is the hallmark of radiation 
GRADE 0 1 2 3 4 
 
 SKIN 
No change 
over baseline 
Follicular/faint 
/dull erythema 
epilation, dry 
desquamation 
decreased 
 sweating 
Tender/bright /bright 
erythema, 
patchy moist 
desquamation, 
moderate 
edema 
Confluent  
moist  
desquamation, 
other than in  
skin folds, 
pitting edema 
Ulceration, 
hemorrhage, 
necrosis 
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pneumonitis. Several patient and treatment related factors are associated with radiation 
pneumonitis. Some of these factors are age, body mass index (BMI), dose/volume and 
exposure to taxane based chemotherapy. Taghian and Burstein  observed an association 
between concurrent or sequential use of taxanes and radiation pneumonitis(38). With the 
use of modern radiotherapy techniques like Three Dimensional Conformal Radiation 
Therapy (3DCRT) and Intensity Modulated Radiation Therapy (IMRT) the chance of 
radiation pneumonitis is low (1-7%). Treatment of radiation pneumonitis is with a short 
course of corticosteroids. Confirmed symptomatic lung fibrosis was very rare at ten years 
and 2 patients (0.2%) in the conventional fractionation arm and 8 patients (0.7%) in the 
hypofrationated arm developed it in the START B trial.    Bronchiolitis Obliterans 
Organizing Pneumonia (BOOP) is another extremely rare pulmonary complication of 
radiation therapy. The condition is seen more commonly in the elderly patients with 
concurrent use of hormonal agents or taxanes. Treatment with long course of 
corticosteroids is the treatment for radiation pneumonitis. 
The scoring of radiation pneumonitis based on RTOG Acute Radiation 
morbidity scoring criteria is given below: 
GRADE           0        1         2          3         4 
LUNG No change Mild 
symptoms of 
dry cough or 
dyspnea on 
exertion 
Persistent 
cough, 
requiring 
narcotics/anti 
tussives, 
dyspnea with 
minimal 
effort, but 
not at rest 
Severe cough 
unresponsive to 
narcotic/antitussive 
agents or dyspnea at 
rest/clinical/radiologic 
evidence of acute 
pneumonitis/intermittent 
oxygen orsteroids may 
be required 
Severe 
respiratory 
insufficiency 
Continuous 
oxygen or 
assisted 
ventilation 
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  Left chest wall irradiation is invariably associated with exposure of the heart. 
Retrospective analyses of studies have used outdated techniques of radiotherapy and have 
reported an increased incidence of cardiac events. It takes almost 15 years for these 
events to occur. But with modern radiotherapy techniques, the recent PMRT trials did not 
show any increase in cardiac side effects. The ten year results of START B trial was 
published recently and showed that the incidence of ischemic heart disease was similar in 
the standard fractionation arm and the hypofractionated arm (0.5 % and 0.4 % 
respectively). However the cardia needs to be protected in this era where the use of 
cardiotoxic agents like anthracyclines and Trastuzumab is on the rise.  
  Lymphoedema is the abnormal swelling of the arm which may occur after 
Modified Radical Mastectomy or more commonly as a sequel of both surgery and 
adjuvant radiotherapy to the axilla. Lymphoedema has various definitions in the 
literature, one of them being, more than 2cm difference in circumference between the 
affected and the contralateral arm measured at fixed points 10cm above and below the 
Olecranon.  
The highest rate of lymphedema is seen in patients who undergo complete axillary 
dissection (levels I-III) followed by axillary irradiation. High BMI, age, hypertension, 
infection, dose prescribed, number of metastatic nodes, number of nodes removed are 
some of the factors associated with higher chance of lymphedema. The fact that there is 
no effective treatment for this condition makes it more distressing. The intent of any form 
of treatment will be palliation of symptoms and to prevent infections on the affected arm. 
Patients are advised to be cautious enough to avoid any trauma or even regular BP 
recording on the affected side.   
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  Second non breast malignancy is another adverse effect of PMRT which is often 
not stressed while obtaining consent. This stochastic effect is not seen until ten years of 
radiation therapy. Approximately 7-8 % of women who undergo post mastectomy 
radiation therapy develop second non breast cancer. But it was also found that there was 
not a significant difference in the rate of malignancy in a similar non irradiated 
population. Reports say that the chance on developing lung cancer is higher in irradiated 
patients who underwent mastectomy than those who underwent breast conservation. 
Increased risk of second malignancy is not evident until about 15 years after the 
treatment.  
Contralateral breast cancer is the most common second malignancy reported.   
Gao and colleagues reviewed more than one lakh diagnosed cases of breast cancer 
between 1973 and 1996 and reported an overall 4.2% incidence of contralateral breast 
cancer. There was no correlation noted when multivariate analysis was carried out. On 
subset analysis, the authors found an absolute 1.6% increase in contralateral breast cancer 
at 20 years post radiation therapy. On the whole there is lack of evidence to state that 
there is a definite correlation between radiation and contralateral breast cancer. 
        These side effects are not particular to hypofractionated radiation therapy and are 
seen in patients undergoing conventional fractionation also.  
2.13 INDIRECT BENEFITS OF HYPOFRACTIONATION 
The benefits of hypofractionated radiation therapy are multifaceted. Not all 
patients receiving radiation therapy live in the proximity of the treatment centre. In our 
country where radiotherapy centres are available only in tertiary hospitals, any given 
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centre would have a considerable proportion of patients coming from distant places to 
access the health care system. These patients usually make arrangements for staying in 
and around the hospital, be it in a lodge or a relative or friend’s residence. Invariably each 
patient will be accompanied by a relative, who also needs to make arrangements for his 
or her absence from work or household. The patient is forced to be away from her family 
for the entire duration of treatment. The expenses include the direct medical cost and the 
indirect cost, for lodging and food. Loss of wages is also a financial burden to the family.  
  Breast cancer patients make up a substantial proportion of patients treated by any 
given treatment unit. When the number of fractions is reduced from 25 to 15, the 
reduction of 10 fractions per patient translates to saving 1000 treatment sessions per 100 
patients treated. This corresponds to an additional 66 patients who could be treated with 
the same number of fractions. This reduces the workload for the treatment machines and 
for the staff.  
 
Treatment is associated with both social and physical implications. The social 
costs are the time lost from normal family life, livelihood and the physical costs are the 
radiation induced injury to the skin, lungs and other organs at risk. 
2.14 ACCEPTANCE OF HYPOFRACTIONATION IN INIDA 
Indian literature on hypofractionated post mastectomy radiotherapy is limited. In 
a study conducted between 1989 to 1992 by Goel et al compared two radiotherapy 
schedules, 40Gy in 17 fractions (2.35Gy per fraction) over 3.2 weeks and 45Gy in 20 
fractions (2.25Gy per fraction) over 4 weeks in patients who have undergone modified 
39 
 
radical mastectomy. Cobalt 60 unit was used for the treatment. Chest wall failure was 
noted in 10% and 5.6 % of patients in the first and second treatment groups respectively. 
Skin reactions, which were reversible, were the commonest side effect in both the groups. 
This study concluded that , both these shorter fractionation schedules are equally 
efficacious and tolerable for the Indian women(39). 
        Another retrospective study from Post Graduate Institute Chandigarh, published in 
2007, assessed 688 patients who have undergone post mastectomy radiotherapy between 
1995 and 2000. The schedule used was 40Gy in 15 fractions using Co 60. The five year 
local control was 94.4 % and frequency of loco regional recurrence was 8.5%.The 
incidence of WHO Grade III dermatitis was  7.1% and acute pneumonitis was seen in 3% 
of patients(40). 
   A recent practice survey which looked into patterns of locoregional treatment 
(2006 - 2008) in breast cancer conducted by Tata Memorial Hospital, published in 2010, 
reported that 67% of Radiation Oncologists approved the standard 50Gy in 25 fractions 
schedule for patients with early breast cancer, after breast conservation surgery. Another 
23% of doctors preferred 45Gy in 25 fractions and surprisingly none of them approved 
hypofractionated radiotherapy. The questionnaire in that survey gave five different 
schedules and the most common schedule (82 %) was 50Gy/25 fractions(41). 
These studies suggest that even though hypofractionated radiotherapy was being 
practiced in our country from as early as 1989; there is still paucity in whole hearted 
acceptance of this shorter radiotherapy schedule. One of the reasons might be the lack of 
availability of Three Dimensional Conformal Radiotherapy facilities across the country, 
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which is safer in delivering this higher dose per fraction. Another hurdle in applying this 
regimen in our country is the limited finances of our patients which precludes 3DCRT for 
them. Then, among the affordable patients, there is a tendency to assume that the longer 
treatment schedule would benefit them more in terms of recurrence of cancer. When 
informed about the higher dose per fraction, there is a fear among some patients 
regarding higher chance of side effects. 
Breast cancer patients form a major proportion of patients being treated in our 
institution and a many of them are able to afford 3DCRT. Even though there is robust 
evidence for safety and efficacy of hypofractionated radiotherapy, our institution was 
continuing the longer (46-50Gy in 23-25 fractions) schedule. With the increase in breast 
cancer patients, the load on the Linear accelerator also increased and hence we proposed 
this study to look into the feasibility of changing over to the shorter regimen for eligible 
patients. 
 
 
 
 
 
 
41 
 
3. MATERIALS AND METHODS 
3.1 HYPOTHESIS: Hypofractionated radiotherapy is a safe, tolerable and effective 
alternative to the conventional radiotherapy in patients with carcinoma breast who have 
undergone Modified Radical Mastectomy (MRM). 
3.2 AIM: To conduct a single arm prospective trial to assess the feasibility and 
tolerability of hypofractionated post mastectomy radiotherapy. 
3.3 OBJECTIVES:  
To document the incidence of acute toxicities in patients treated with hypofractionated 
radiotherapy. 
Period of study: One year, from January 2013 to November 2013 
Setting: 
The study was conducted in the Department of Radiation therapy in Christian Medical 
College. The proposal of the study was approved by the Institutional Review Board (IRB) 
and the Ethics Committee (EC). All post mastectomy patients who were seen in the dept. 
of Radiotherapy were screened for the study according to the preset inclusion and 
exclusion criteria. 
The inclusion and exclusion criteria were the following:  
Inclusion Criteria: 
1. Age above 18 years and less than 70 years 
2. Any patient requiring post mastectomy radiotherapy. 
3. Enrollment possible within 42 days of surgery or last cycle of Chemotherapy 
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Exclusion Criteria: 
1. Patients who had Breast Conservation surgery 
2. Collagen Vascular disease 
3. Poor performance status (ECOG >3) 
4. Pregnancy and breastfeeding. 
5. Patients who had immediate reconstruction after mastectomy. 
6.  Close or positive surgical margin 1 mm or less 
7. Axillary nodal involvement with extranodal extension  
8.  Metastatic breast cancer 
9. Prior history of radiation therapy to the chest. 
10. Transmural myocardial infarction within last 6 months 
11. Medical, psychiatric or other condition that may prevent the patient from 
receiving the protocol therapy or informed consent.   
12. Unstable angina or congestive heart failure requiring hospitalization within the 
last six months.            
13. History of interstitial lung disease or active lung infection        
3.4 SAMPLE SIZE 
This is a pilot study to assess the feasibility of hypofractionated radiotherapy in patients 
with carcinoma breast. It was decided to study 20 patients for assessing the tolerability. 
3.5 METHOD  
All female patients diagnosed to have carcinoma breast, who required adjuvant radiation 
therapy were screened using the inclusion and exclusion criteria. Eligible patients were 
explained about the study, its purpose, benefits and side effects in detail. An information 
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sheet was given to the patient which provided details of the study. Patients who were 
willing to participate in the study gave their consent in a prefilled consent form in 
writing.  
 
Patient with carcinoma breast                                Willingness          
with indications for PMRT                                              for 3DCRT                                 
                                                                                                                              
                                                                                    
                                                                                             Screening 
                                                                               Inclusion/exclusion criteria 
 
                                                                       
                                                                               Informed consent obtained                   
 
                                                                                                  
                                                                          Confirm adequate wound healing 
                                                                          Baseline Blood tests 
                                                                          ECHO, PFT-Lung volumes, Spirometry  
 
                                                                                      
 
                                                                        Simulate on Breast board,                                                                                                                                                                                                                                                
                                                                        3 centres marked, tattooed           
                                                                        Set up documented 
 
                                                                                                  
                                                                                 
                                                                      Scar wired-radio opaque wire 
                                                                      Radio opaque spheres- for the 3 centres                                                                                                                                                                                           
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                                                 Planning CT scan: Flat couch 
                                                 IV contrast, C4 to Adrenals 
                                                 5 mm cuts 
                                                 Images transferred to Eclipse External Beam Planning 
                                                 V 10.0.42; Varian Medical Systems, Palo, Alto, CA 
 
 
                                                  
                                                                                 
                                                                CTV, OARs contoured                                                          
                                                                according to RTOG 
                                                                Guidelines                                               
 
                                                                                                                        
 
 
                                                                    Volume finalisation                                                                                                                          
                                                                    Finalised volume                                                
                                                                    transferred to                        
                                                                    PLATO RTS                                                                                                                  
                                                                    Version 2.7.7 
 
 
 
                              
                                                          Planning- Gantry angle optimization 
                                                          MLC  
                                                          Calculation 
                                                          Dose Prescription  
                                                          (4005cGy/15 fractions) 
                                                           
 
                                                                                             
                                                                  Generation of DVH 
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                                                  Plan evaluation and finalisation 
                                                           
                                   
                                Treatment execution on Linear Accelerator 
                                                 (Siemens, PRIMUS) 
 
 
                                        Weekly clinical assessment 
                                        Close monitoring for dermatitis 
                                        Clinical photograph in case of 
                                        significant dermatitis 
                                   
                                   
 
                         Follow up for six weeks after completion of RT 
                                                
                                         Repeat PFT after three months 
                                                                                  
Radiotherapy was scheduled as soon as the surgical wound has healed or after three 
weeks of prior chemotherapy. Routine blood tests were done to rule out neutropenia. 
Patient immobilization was done in the simulator using a breast board. CT centres were 
marked and tattooed. The clinical boundaries of chest wall were marked on the body. The 
details of the patient setup were documented. On the day of the scan, the CT centres and 
clinical boundaries of the chest wall, scar and the drain sites were marked with 
radiopaque markers. Contrast enhanced CT scan from C4 to the level of adrenals was 
obtained in the treatment position with a slice thickness of 5 mm.  
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The CT images were imported to the planning system (Eclipse External Beam Planning 
V10.0.42; Varian Medical Systems, Palo, Alto, CA). The RTOG contouring guidelines 
were followed in delineating the Clinical Target Volume and the Organs at Risk. 
Regions treated 
Chest wall 
Supraclavicular region: Supraclavicular field was added if there were four or more 
positive axillary nodes.  
RTOG guidelines 
The RTOG contouring guidelines were used to contour the chest wall, supraclavicular 
regions and the organs at risk.  
Chest wall- Clinical Target Volume (CTV) 
The chest wall craniocaudally extends between the caudal border of head of clavicle and 
the level where there is loss of CT apparent contralateral breast. Antero-posteriorly the 
contour extends between the skin and the rib-pleural interface (includes Pectoralis muscle, 
chest wall muscles and ribs). The chest wall contour extends between the rib-sternal 
junction to the mid axillary line (excludes Latissmus dorsi muscle) 
Supraclavicular region- Clinical Target Volume (CTV) 
The supraclavicular region was contoured craniocaudally between the caudal edge of 
Cricoid cartilage to the caudal edge of the Clavicular head and antero-posteriorly between 
the Sternocleidomastoid muscle and the anterior Scalene muscle. Medially the volume 
excludes the trachea and thyroid gland and the lateral edge of the Sternocleidomastoid 
muscle forms the lateral boundary cranially and the junction of first rib and clavicle 
caudally.   
47 
 
Organs at Risk (OAR) 
Lungs: Bilateral lungs were contoured separately and combined lung volume is also 
generated. 
Heart: The superior aspect (or base) begins at the level of the inferior aspect of the 
pulmonary artery passing the midline and extend inferiorly to the apex of the heart. 
Dose Prescription 
Total dose 
(Gy) 
Dose per 
fraction (Gy) 
No of 
Fractions 
Fractions per 
week 
Treatment 
time (weeks) 
40.05 2.67 15 5 3 
 
3.6 STEPS INVOLVED IN 3D-CRT 
1. Patient immobilization was done on breast board and the clinical references and the 
centers were marked and tattooed. A planning CT scan of thorax was obtained with 5mm 
slice thickness.  
2. Delineating the Clinical Target Volume (CTV) and the Organs at Risk (OAR) on the 
planning CT images at the contouring station was done.   
 3. Beam selection and planning was done to see dose distribution using Plato treatment 
planning system. Both 6MV and 15 MV beams were used. Bolus was applied whenever 
applicable.  
4. Plan evaluation was done using Dose Volume Histogram (DVH) and isodose 
distribution after which the final plan was selected. 
5. Digitally Reconstructed Radiographs (DRR) were developed for comparison with the 
electronic portal image.  
6. Treatment execution 
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The following guidelines were considered for finalizing the plan: 
Lower dose limit: 
More than 95% of the Clinical Target Volume should receive more than 90 % of the 
prescribed dose. 
Upper dose limit 
Less than 2 % of the volume should receive more than or equal to 107 % of the 
prescribed dose.  
Less than 7 % volume should receive more than or equal to 105 % 
Global max should be less than 110 % of the prescribed dose. 
Ipsilateral lung 
The volume of ipsilateral lung receiving 12Gy (V30%) or V12Gy) should be less than 17 %. 
Heart 
The volume of heart receiving 2Gy should be less than 30%. 
The volume of heart receiving 10Gy should be less than 5%. 
Contralateral breast 
Maximum dose to the contralateral breast is less than or equal to 330cGy. 
 
3.7 DATA ON DOSE VOLUME PARAMETERS 
The details regarding the dose-volume parameters were obtained from DVH and entered 
in a data sheet. For those patients with chest wall and supraclavicular region as clinical 
target, the DVH combining both the regions was used for obtaining the relevant dose-
volume parameters.  
49 
 
3.8 WEEKLY ASSESMENT 
The patients on hypofractionated post mastectomy radiation therapy were monitored on a 
weekly basis by one of the investigators. Clinical examination was done particularly 
looking for dermatitis over the chest wall. Dermatitis was graded according to the RTOG 
Acute Radiation Morbidity Scoring Criteria. Weekly follow up details were entered in an 
assessment form (Appendix No 2). Patient demographic data was entered in a data sheet 
(Appendix No 1). Clinical photographs were taken if any patient developed significant 
dermatitis. Treatment was interrupted in case of Grade 3 dermatitis. Radiation therapy 
was not resumed until the reactions subsided to Grade I.                                                                                         
3.9 POST TREATMENT FOLLOW UP 
Patients were followed up for six weeks post radiation therapy to assess for radiation 
dermatitis.  Pulmonary Function Test is advised three months after the completion of the 
treatment. 
3.10 STATISTICAL ANALYSIS 
Data entry was done in Micrsoft Excel and was analysed using SPSS 16.0 (Statistical 
Package for Social Sciences). Frequencies and percentages were calculated for discrete 
variables like grades of radiation dermatitis. Mean, median and standard deviation were 
calculated for continuous variables such as age, BMI etc. The association between the 
outcome variables was tested using Chi square test. The data was represented graphically 
using bar diagrams and histograms. Correlation between variables was studied. 
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4. RESULTS 
 
    The target sample size for this feasibility study was 20. Twelve patients were recruited 
by the end of November 2013.  
4.1 OVERVIEW OF PATIENTS 
 
         The study group included 12 patients diagnosed to have carcinoma breast and had 
undergone Modified Radical Mastectomy. Six of them were local patients, five hailed 
from other parts of Tamil Nadu, Kerala, Andhra Pradesh and West Bengal. One of the 
patients was here for treatment from Bhutan.  The majority (58%) of patients belonged to 
the age group 46-55 years and the mean age was 50 years (Figure 4.1). The study group 
consisted of 42% healthy individuals, 42% overweight, 8% with Grade I and another 8% 
with Grade II obesity. Diabetes mellitus and hypertension was the most common co-
morbidities noted. There were seven patients with left sided breast cancer and five with 
right sided disease.  Two women had mastectomy elsewhere. There were six patients 
with Stage IIIA, four with IIA, one with IIIB and another patient who underwent surgery 
at a different centre was staged as TxNxM0. Four of the patients had upfront surgery, 
seven received neoadjuvant chemotherapy and one patient received neoadjuvant 
hormonal therapy. Five patients received treatment to the chest wall and supraclavicular 
region where as seven of them received only chest wall irradiation. The patient 
characteristics are given in Table 4.1.  
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Table 4.1.Demographic and clinical characteristics 
Tamil Nadu 
Kerala 
Andhra Pradesh 
West Bengal 
Bhutan 
7 
2 
1 
1 
1 
Age 
 
<35 
36 - 45 
46 – 55 
56 – 65 
>65 
 
 
1 
2 
7 
2 
0 
BMI 
Healthy 
Over weight 
Grade I obesity 
Grade II obesity 
 
 
5 
5 
1 
1 
 
Premenopausal 
Postmenopausal 
 
7 
5 
Patients with no co-morbidities 
 
Patients with co-morbidities 
 
 
 
5 
 
7 
Diabetes mellitus - 1 
Hypertension- 2 
Diabetes mellitus, Hypertension- 1 
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Dyslipidemia- 1 
Diabetes mellitus, Hypertension, 
Coronary artery disease- 1 
Hypetension, Bronchial Asthma- 1 
 
Laterality 
 
Left 
  Right 
  
 
7 
5 
 
 
Stage 
II A 
IIIA 
IIIB 
 TxNxM0 
 
4 
6 
1 
1 
 
Estrogen receptor 
Positive 
Negative 
 
8 
4 
Progesterone receptor 
Positive 
Negative 
 
6 
6 
Her 2 neu 
Positive 
Negative 
 
2 
10 
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Triple negative 4 
Had neoadjuvant chemotherapy 
 
 
Did not have neoadjuvant chemotherapy 
Had adjuvant chemotherapy 
 
 
 
Did not have adjuvant chemotherapy 
7 
Anthracycline - 4 
Anthracycline and Taxane - 3 
5 
11 
Anthracycline- 4 
Taxane – 4 
Anthracycline and Taxane – 3 
1 
Regions treated 
Chest wall  
Chest wall and supraclavicular region 
 
7 
5 
 
All the patients completed the prescribed treatment without any major complications. The 
patients were followed up for a period of six weeks to assess acute toxicity. One of the 
patients subsequently developed distant metastasis (pulmonary) and is currently on 
systemic therapy. Others are disease free at the time of last follow up. 
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0
1
2
3
4
5
6
7
<35 36-45 46-55 56-65 >65
YEARS 1 2 7 2 0
AGE DISTRIBUTION
42%
42%
8%
8%
BMI PROFILE
healthy 18.5 to 24.9
overweight  25 to 29.9
grade 1 obesity 30 to 
34.9
grade 2 obesity 35 to 39.9
Figure 4.1: The majority of patients belonged to the 46-55 years age group 
     Figure 4.2: Obese patients formed only 16% of the study population 
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FREQUENCY 7 5
A
x
LATERALITY
67%
33%
ESTROGEN RECEPTOR STATUS
POSITIVE NEGATIVE
 
Figure 4.3: Seven out of 12 patients had left sided breast cancer 
Figure 4.4: The majority of the patients were Estrogen receptor positive. 
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50%50%
PROGESTERONE RECEPTOR STATUS
POSITIVE NEGATIVE
17%
83%
HER 2 NEU STATUS
POSITIVE NEGATIVE
Figure 4.5: Equal distribution of Progesterone receptor status  
Figure 4.6: Most of the patients were her 2 neu positive 
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4.2 DVH PARAMETERS 
4.2.1 CLINICAL TARGET VOLUME 
The lower dose limit applied for the CTV was that more than 90% of the CTV should 
receive 95% or more of the prescribed dose (V95% > 95%). The upper dose limit 
constraints were, V107% <2%, V105% <7% and Global maximum <110%. 
 
 
 
 
IIA IIIA IIIB TxNxM0
4
6
1 1
Clinical stage
Figure 4.7: Stage wise incidence of breast cancer in the study group  
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CTV coverage was analyzed by dividing the cases into two groups according to the 
regions treated (Table 4.3). 
Chest wall and Chest wall along with supraclavicular region 
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 11 12
CTV coverage
V90%
V95%
V100%
PATIENT V90% V95% V100% 
1 95.54 91.55 53.2 
2 97.38 87.98 28.18 
3 99.04 96.02 71 
4 99.37 95.23 47.99 
5 94.05 86.33 4.3 
6 98.63 95.66 60.44 
7 98.17 92.06 45.07 
8 98.8 96.8 58.5 
9 96.4 91.6 69.1 
10 98.1 94.2 71.8 
11 98.34 92.52 47 
12 97 91.1 60.6 
Table 4.2: CTV Coverage 
Figure 4.8: Bar diagram showing the CTV V90%, V95% and V100%   on Y axis across patients on X 
axis. 
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The median CTV V 95% was 92.52% when chest wall was treated alone and 91.60% when 
chest wall and supraclavicular regions were treated. Both CTV V90% and V95%   were 
better when chest wall alone was treated, but this difference was not statistically 
significant. 
Table 4.3: CTV coverage with respect to regions treated 
 
CTV 
 
Chest wall 
 
Chest wall and supraclavicular 
regions 
p value  
1
st
 
quartile 
 
 
Median 
 
3
rd
 
quartile 
 
1
st
 
quartile 
 
 
Median 
 
 
3
rd
 
quartile 
 
V90%  95.54  
 
98.34 
 
99.04 
 
96.70 
 
 
97.38 
 
98.45 
0.530 
V95%  91.55  
 
92.52 
 
95.66 
 
89.54 
 
 
91.60 
 
95.50 
0.755 
V100% 
 
45.07 
 
47.99 60.44 43.34 
 
60.60 
 
70.45 
0.343 
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The median V90% was 98.34% in patients who received chest wall radiation alone 
compared to 97.38% in patients who received supraclavicular radiation in addition to the 
chest wall radiation (Fig 4.9). This variation in V90% was not statistically significant (p 
value 0.530). The range of V90% values was broader when only chest wall was treated 
(Table 4.3)          
Figure 4.9: Comparison of V90% among two groups – according to regions treated  
61 
 
 VA
 
 
The median V95% values were 92.52% and 91.60% for chest wall irradiation alone and 
combined chest wall-supraclavicular irradiation respectively (Table 4.3). The range of 
V95% was similar among the two groups and ranged between 86.33–96.02% and 87.98–
96.80 (Fig 4.10). The first and third quartiles were 91.55% and 95.66% in the chest wall 
group (Table 4.3). 
Figure 4.10: Comparison of V95% among two groups –according to regions treated 
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The median V100% was 60.6% in the chest wall-supraclavicular group and 47.99% in the chest 
wall alone group (Table 4.3, Fig 4.11).   
 
UPPER DOSE LIMITS 
      The hot spots, V105% and V107% were well within the tolerance limits (<7% and 
<2% respectively). The hot spots were analyzed by dividing the patients into two groups 
according to the regions treated: 
Figure 4.11: Comparison of V100% among two groups – according to regions treated 
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Chest wall and Chest wall & supraclavicular region 
Table 4.4: Upper dose limits with respect to regions treated 
CTV 
Chest wall Chest wall – supraclavicular 
p 
value 1
st
 
quartile 
 
Median 
3
rd
 
quartile 
1
st
 
quartile 
 
Median 3
rd
 quartile 
G max 106 106 107 104 106 106.50 0.343 
V105% 1.96 3.43 5.50 0.45 3.10 7.05 0.876 
V107% 0 0.14 0.49 0 0 0.35 0.639 
 
The CTV Global maximum doses ranged between 104-108% in the group of patients 
who received chest wall radiation and 104-107% in the group of patients who received 
the supraclavicular irradiation in addition. The median Global maximum dose was same 
(106%) in both the groups (Table 4.4, Fig 4.12). 
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Figure 4.12: CTV global maximum according to regions treated  
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The median V 105% was 3.43% and 3.10% respectively for chest wall alone and 
combination of supraclavicular and chest wall regions (Table 4.4). The values ranged 
between 0 and 9 % in both the groups (Fig 4.13). 
Figure 4.13: Comparison of CTV V105% among the two groups based on regions treated. 
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Figure 4.14 shows that the range of V107% was 0 – 0.78% in the chest wall group and 0-
0.50% in the chest wall-supraclavicular group. The median value was 0 in the two- 
regions group, where as median V107% was 0.14% in the single region group. 
 
 
  
Figure 4.14: Comparison of V107% among the two groups based on regions irradiated. 
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CTV COVERAGE AND BMI 
There was a positive correlation between BMI and CTV 95%, which implied that higher 
the BMI, higher is the CTV V95%. But this was not statistically significant in view of the 
small sample size (Figure 4.15). 
 
 
 
Figure 4.15: BMI and CTV V95% 
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4.2.2 ORGANS AT RISK 
 
The organs at risks studied were ipsilateral lung, heart, contralateral lung, combined lung 
and contralateral breast. V10Gy, V12Gy and V20Gy for the ipsilateral lung and V2Gy and V10Gy 
for the heart were documented. The dose constraint attempted to achieve was the volume 
of the ipsilateral lung receiving 12Gy to be less than 17%. The ipsilateral lung volume 
receiving ≥12Gy ranged from 7.43% to 35%. The contralateral lung V10Gy and V20Gy were 
found to be 0, which means that no part of the contralateral lung received 20Gy or 10Gy.  
Table 4.5: Ipsilateral Lung volumes receiving 10Gy, 12Gy and 20Gy 
Patients V10Gy V12Gy V20Gy 
1 20.99 20.2 18.12 
2 21.61 20.85 18.36 
3 20.06 19.42 17.43 
4 14.99 14.19 11.75 
5 19.06 18.18 15.51 
6 15.62 14.93 12.91 
7 7.94 7.43 5.83 
8 22.4 21.1 17.3 
9 37.6 35 32.1 
10 30.8 29.5 25.7 
11 16.96 16.23 13.97 
12 26.1 25.2 21.5 
Mean 21.17 20.18 17.54 
SD 7.72 7.25 6.77 
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The dose constraint for ipsilateral lung could be met for only four patients (V12Gy 
<17%). The remaining 8 patients had >17% of their ipsilateral lung receiving 12Gy or 
more. Among these 8 patients, 3 of them had V12Gy ≤ 20% (Table 4.5, Fig 4.16). 
Volume of lung irradiated according to the regions treated 
The V10Gy , V12Gy  and    V 20Gy  which are the volumes of lung receiving 10Gy, 12Gy  and 
20Gy respectively was higher for those patients who had supraclavicular field in addition 
to the chest wall field. The Mann-Whitney test was applied and it was found that the 
V10Gy   and   V 12Gy    were significantly (p value 0.003) higher when both the regions were 
included as the target (Table 4.6, Fig 4.17, 4.18, 4.19).  
 
Figure 4.16: Plot showing the lung volumes receiving 10Gy, 12Gy and 20Gy in percentages 
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V10Gy ranged between 7.94 % and 20.99 % in the group of patients who received chest 
wall  
irradiation alone. The range of V10Gy was 21.61% to 37.6% in chest wall-
supraclavicular group.  
Figure 4.17 shows that the median V10Gy was higher in the chest wall-supraclavicular 
group than that of the chest wall alone group (26.10 % vs 16.9 % , p value 0.003). 
 
Lung 
volume 
               Chest wall 
 
Chest wall and                                            
supraclavicular 
p value 
1
st
 
quartile 
 
 
Median 
3rd 
quartile 
 
 
 
1
st
 
quartile 
 
 
Median 
3rd 
quartile 
 
V10Gy 14.99 16.9 20.06 22.34 26.10 34.20 0.003 
V12Gy 14.19 16.23 19.42 20.98 25.2 33 0.003 
V20Gy 11.75 13.97 17.3 17.83 21.5 29.25 0.010 
Table 4.6: Ipsilateral lung dose volume data based on regions treated 
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Figure 4.17: Comparison of V10Gy according to regions treated 
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The median V12Gy in the group of patients who had supraclavicular region in addition to 
the chest wall was 25.2% compared to the group of patients who received only chest wall 
irradiation 16.23% (p value 0.003). The first and the third quartiles values of V12Gy for 
chest wall irradiation was 14.19 %  and 19.42%, which implies that 50 % of patients in 
this group had their V12Gy values in this range. 
 
Figure 4.18: Comparison of V12Gy among groups of patients according to the regions treated 
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The median values were 13.97 % and 29.25 % respectively for patients who received 
radiation to chest wall alone and supraclavicular-chest wall irradiation.  Median V20Gy 
was significantly higher in the patients who received supraclavicular treatment in 
addition to chest wall (p value 0.010). 
Combined lung: Combined lung volume receiving 10Gy (V10Gy) was less than 17% in 
eleven of the twelve patients. One patient had a V10Gy of 19%. 
 
 
 
Figure 4.19: Comparison of V20Gy among two groups of patients according to the regions treated 
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HEART 
The dose constraints we attempted to achieve was V10Gy ≤ 5% and V2Gy ≤ 30%. V2Gy 
≤30 % could be achieved in 7 out of 12 patients and V10Gy ≤ 5 % was achieved in 6 out 
of 12 patients. 
Volume of heart irradiated according to laterality of the disease: 
The volume of heart receiving 2Gy and 10Gy were significantly (p value 0.003) higher in 
patients with left sided breast cancer (Table 4.7, Fig 4.20, 4.21).  
Table 4.7: Heart dose-volume parameters according to laterality of the disease 
Heart volume Left chest wall Right chest wall p value 
 
 
 
V2Gy 
1
st
 quartile 
 
Median 
3
rd
 
quartile 
 
1
st
 
quartile 
 
Median 
3rd 
quartile 
 
 
 
 
0.003 27.66 35.7 44.07 2.35 2.80 9.21 
V10Gy 8.31 12.70 14.26 0 0 0.5 0.003 
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The median V2Gy in patients with left sided disease was 35.7% and 2.8% in patients 
with right sided disease (Table 4.7). The difference in the volume of heart receiving 2Gy 
is depicted in Figure 4.20. The first and third quartiles for V2Gy in left side irradiation 
were 27.66 % and 44.07 %( Table 4.7 ).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Figure 4.20: Comparison of V2Gy among left and right chest wall irradiation 
76 
 
 
 
Median V10Gy in the patients who received left chest wall irradiation was 12.7% where 
as the median value in right chest wall irradiation was 0%. Figure 4.21 depicts the range 
of V10Gy values among the two groups. 
Contralateral breast: The dose constraint that we tried to achieve was to keep the mean 
dose to the contralateral breast ≤ 330cGy. The mean contralateral breast dose ranged 
between 38cGy and 126.5cGy. The mean of all the patients’ contralateral breast mean 
Figure 4.21: Comparison of V10Gy among left and right chest wall irradiation 
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dose was 65.24cGy. All the patients had contralateral breast dose well within the 
tolerance limit.  
 
4.3 ACUTE TOXICITIES 
Patients tolerated the treatment well without any Grade IV toxicities. The acute toxicities 
that were noted in the study group were fatigue, dermatitis and mucositis (throat 
irritation). 
Dermatitis and fatigue were the most common side effects noted (Table 4.8, Fig 4.22). 
None of the patients developed features of acute radiation pneumonitis.   
       
Table 4.8: Acute side effects  
 
week 1 week 2 week 3 week 4 week 5 week 6 week 7 week 8 
 
 week 9 
 
Fatigue 1 5 3 1 0 0 0 0 0 
Dermatitis 2 8 12 4 3 1 0 0 0 
Cough 0 4 3 0 0 0 0 0 0 
Throat 
irritation 
0 2 1 0 0 0 0 0 0 
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DERMATITIS 
None of the patients developed Grade IV dermatitis. One patient developed Grade III 
dermatitis by week 4 (the week after completion of radiotherapy). She completed 
treatment on 24.4.2013, Grade III reaction was documented on 1.5.2013, and by 8.5.2013 
the reaction subsided Colour plates 1,2,3). Majority (10 out of 12) of the patients had 
only Grade I dermatitis and only one patient developed Grade II dermatitis (Table 4.9, 
Fig 4.23). 
Table 4.9: Week wise incidence of dermatitis 
DERMATITIS WEEK 1 WEEK 2 WEEK 3 WEEK 4 WEEK 5 
Grade I 2 8 11 2 2 
Grade II 0 0 1 1 0 
Grade III 0 0 0 1 0 
Grade IV 0 0 0 0 0 
0
2
4
6
8
10
12
week 
1
week 
2
week 
3
week 
4
week 
5
week 
6
week 
7
week 
8
week 
9
Acute side effects
Fatigue
Dermatitis
Cough
Throat irritation
Figure 4.22: Acute side effects during and after treatment 
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FATIGUE 
Only 5 of the patients developed mild fatigue during the three week of treatment. They 
were able to continue the activities without any limitations. 
 
OVERALL TREATMENT TIME 
The overall treatment time varied between 18 to 24 days. The mean overall treatment 
time was 20.83 days.  
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10
12
WEEK 1 WEEK 2 WEEK 3 WEEK 4 WEEK 5
Dermatitis
Grade I Grade II Grade III Grade IV
Fig 4.23: Week wise incidence of dermatitis 
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TREATMENT BREAKS 
There were no breaks in treatment due to patient related reasons. Three patients had 1 day 
each of break in treatment due to machine related issues. 
FOLLOW UP 
Patients have been followed up regularly and the longest follow up is 9 months. None of 
the patients had local recurrence within this short follow up period. Six out of the twelve 
patients had completed more than three months of follow up at the time of this analysis. 
Out of these six patients only three had pre and post radiotherapy Pulmonary Function 
Tests done. Pre and post radiation therapy Forced Vital Capacity (FVC) was compared, 
the results of which are given in Table 4.10 
Table 4.10 Pre and post radiotherapy FVC 
FVC in litres FVC in % 
(Post bronchodilator/predicted) 
 Pre RT Post RT Pre RT Post RT 
1 2.92 2.52 95.4 83.6 
2 1.61 1.69 62.5 71 
3 1.79 1.76 66.9 64.8 
  
FVC above 80 % is normal. There was no significant change in FVC values pre and post 
irradiation. One of the patients had low FVC at baseline and this was attributed to 
Bronchial asthma.  
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5. DISCUSSION 
      Hypofractionated radiotherapy for carcinoma breast is a safe and effective 
form of treatment in terms of toxicities, locoregional tumor control and 
survival. Our study focused on testing this hypothesis in our patients who are 
heterogeneous among themselves, but at the same time quite different from 
the population that were recruited in the landmark trials on hypofractionation 
for breast carcinoma. The UK Standardization of Breast Radiotherapy 
(START) trials are the landmark trials which forms the broad base for 
evidence for hypofractionated radiotherapy for patients with breast cancer. 
START B trial was a randomized controlled trial which compared the 
conventional standard schedule with the hypofractionated regimen (40Gy in 
15 fractions, 3 weeks). The patients in the trial had breast conservation 
surgery predominantly and only about 8% had undergone mastectomy. We 
conducted a single arm, prospective study to assess the feasibility and 
tolerance of hypofractionated radiotherapy in patients who have undergone 
mastectomy. 
            The CTV coverage in patients who received supraclavicular regional 
irradiation in addition to the chest wall irradiation was as good as in patients 
whose chest wall only was treated (Table 4.3). In our study, it was noted that 
as the BMI of the patient increased, the CTV coverage (V95%) also increased 
(Fig 4.15). But, Koh et al has reported that in obese patients, the coverage for 
supraclavicular volume tends to be poor as the supraclavicular fossa will be 
deep. They recommend IMRT for better coverage of supraclavicular region, 
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especially for obese patients(42). Out of the twelve patients in our study, only 
five patients received supraclavicular radiation and hence it was not feasible 
to analyze correlation between BMI and CTV coverage in this subgroup as the 
numbers are small. 
          The dose constraints for ipsilateral lung dose could not be met for all 
patients especially in those who received supraclavicular irradiation (Table 
4.6). Addition of supraclavicular irradiation has contributed significantly to 
the lung dose. This was  consistent with the data from Yang et al, which also 
reports higher lung dose with supraclavicular irradiation(43). The constraint 
was extrapolated from the protocol of the Fast Forward trial which is set for 
hypofractionated whole breast irradiation, whereas our patients received post 
mastectomy radiotherapy(44). This could be the explanation for not being able 
to meet the dose constraint for lung in most of the patients in our study.  
      The volume of heart receiving 2Gy should be less than or equal to 30% - 
again a constraint followed in the Fast Forward trial. The median V2Gy in our 
study population was 35.7% in patients who received left chest wall 
irradiation (Table 4.7). The cardiac toxicities can take up to 15 years to 
develop and hence these patients need to be followed up on long term basis. 
                  In our study, it was difficult to attain optimum balance between 
target coverage and dose constraints to organs at risk using 3DCRT in a subset 
of patients. These were patients with left sided tumour and those who required 
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supraclavicular irradiation. These patients may benefit from IMRT in terms of 
target coverage and dose to organs at risk. 
     There were 12 patients in the study and there were no incidence of any 
form of Grade IV acute toxicity in them, during the three weeks of treatment 
and six weeks of follow up (Table 4.9).   This was in concordance with the 
results of a study by Hijal et al, which assessed dermatitis in patients 
undergoing hypofractionated radiotherapy following breast conservation. 
They reported that most of the patients developed Grade I dermatitis only(45). 
Among the 156 evaluable patients, five patients developed Grade III 
dermatitis and no patient developed Grade IV toxicity. Indication for axillary 
radiation was an exclusion criterion in our study. Axilla has abundant sweat 
glands and the presence of skin creases makes it the commonest region which 
develops moist desquamation(46).  
 The low incidence of serious dermatitis in our study might be due to the fact 
that patients who required axillary radiation were excluded from our study, 
which might be true for the study done by Hijal et al also. This means that, 
safety of hypofractionated radiotherapy needs validation in patients who 
requires axillary irradiation.  One of the patients developed Grade III 
dermatitis, in the week following completion of treatment. The dermatitis 
subsided to Grade I, within a week with conservative measures. But Somaya 
et al has reported that dermatitis lasts longer (about 5 weeks) in patients who 
receive hypofractionated radiotherapy(47). The DVH of this particular patient 
was reviewed to find out if any hot spot was on the skin. There were no high 
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dose regions on the skin.  The possible reasons for the occurrence of Grade III 
dermatitis could be that her BMI was high (29.8 kg/m
2 
,overweight) and the 
skin creases in the lateral aspect of chest wall, towards the axilla. Though she 
was a Diabetic, the skin reactions healed within a week without getting 
secondary infection. Long term cosmetic outcome was better in the 
hypofractionated arm of the START B trial. As our study included only post 
mastectomy cases, cosmesis was not an outcome variable. 
Limitations  
         The number of patients included in the study was small. Due to the small 
sample, some of our results were not statistically significant. Patients who 
required axillary irradiation were not included in the study, thereby limiting 
our experience with hypofractionated radiotherapy in treating the axilla. The 
Left Anterior Descending (LAD) coronary artery is the structure that receives 
maximum dose when left chest wall is irradiated(48). In our study, dose to 
LAD was not studied. LAD coronary artery is the structure that is commonly 
affected by myocardial infarction. 
   The benefits of hypofractionated radiotherapy, in terms of financial benefits 
and Quality of Life of patients were not studied. Late effects on normal tissues 
require long term follow up. Locoregional control also requires minimum of 
five years of follow up. This was not feasible during the term of this study.   
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Recommendations 
     Randomized controlled trial comparing conventional and hypofractionated 
radiation therapy in Indian context in the treatment of whole breast and post 
mastectomy will help to answer the uncertainties prevailing now. Future 
studies need to address dose received by LAD coronary artery. Sub studies 
such as Cost effectiveness and Quality of life will address the additional 
benefits achieved by hypofractionated regimens. A large proportion of our 
patients still cannot afford 3DCRT, and so safety and effectiveness of 
hypofractionated radiotherapy needs to be investigated in patients treated with 
conventional radiotherapy with using either telecobalt megavoltage beam or 
megavoltage x-rays.  
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6.CONCLUSION 
                  Hypofractionated post mastectomy irradiation was well tolerated by 
our patients in terms of acute toxicities. Patients completed treatment without 
any delay or treatment breaks. There were no significant toxicity upto six 
weeks post treatment. The rate and severity of acute side effects were 
comparable with conventional radiotherapy. Long term effects on the lung, 
heart and contralateral breast needs to be studied. Patients were very satisfied 
about the convenience of this shorter radiotherapy schedule. As far as 
feasibility was concerned, we conclude that Three Dimensional Radiotherapy 
based hypofractionation might not be feasible in all patients. There is a subset 
of patients who may benefit from IMRT. Obese patients, with left sided disease 
and who also require supraclavicular irradiation might benefit from IMRT. The 
fact that supraclavicular radiation has significantly contributed to the lung dose 
even in conformal radiotherapy, where in the volume is relatively small, further 
urges us to be cautious while planning the supraclavicular field conventionally.  
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II 
INFORMATION SHEET 
CHRISTIAN MEDICAL COLLEGE, VELLORE 
DEPARTMENT OF RADIOTHERAPY 
Prospective single arm study to assess the feasibility and tolerability of hypofractionated 
postmastectomy radiotherapy in patients with carcinoma breast. 
 
                                                        INFORMATION SHEET 
This is  a type of research study. The entire procedure will be explained to you in detail. Only 
those patients who wish to participate in it will be included in the study. Please find time to 
think about it and make a decision about taking part in it. You may discuss this with your 
family and friends before you make up your mind.  
You are being offered to take part in this study because you have breast cancer and you have 
undergone surgery, but require further treatment with radiation therapy to reduce the chances 
of disease coming back. 
Why is this study being done? 
Studies have shown that, in patients with breast cancer,  giving radiation therapy to the 
chest,  after removal of breast help to reduce the chance of cancer coming back. This is 
commonly given over five weeks -Monday to Friday, five days a week. Recent studies 
have shown that, the chance of cancer control is same,  if  radiation therapy is given in 
higher dose per day over three weeks instead of the five weeks treatment. This makes the 
treatment shorter, with equal efficacy. If you take part in this study, you will receive the 
new short treatment schedule which is well proven to be safe and effective.  
How many patients will take part in this study? 
We are planning to offer this short radiation therapy treatment to 20 patients. 
If you take part in this study what will you have to do? 
Once the wound after the surgery heals, you will be offered radiation therapy, if indicated 
in your case. If you take part in the study you  will receive 15 days of treatment, Monday 
to Friday, every week.  Each day, the treatment may take about 15 minutes. The total 
duration of your treatment will be three weeks. You can involve yourself in the normal 
daily activities of life while on treatment. You will need to attend clinical examination 
once a week while on treatment and for atleast six weeks after completing radiation 
therapy, to look for development of skin reaction over the chest wall. 
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Before starting the treatment:You will need to undergo some tests before starting the 
treatment with radiotherapy. It is mandatory to do these tests prior to treatment even if 
you are not taking part in the trial.These are the tests: 
Blood tests 
Chest X ray 
Ultrasound scan of the abdomen 
Lung Function Tests 
ECHO 
 
During the study 
 
Once you complete the tests and agree to take part in the study , the treatment starts and 
weekly once you need to meet the doctor. This is usual practice even for patients who are 
not in any study. This weekly visit will include history and physical examination to 
document any skin reaction. The doctor will assess how you are tolerating the treatment. 
Clinical photographs of the irradiated area will be taken on alternate weeks while on 
treatment and during the six weeks of follow up. 
 
After the treatment 
 After completion of the treatment, you will be asked to come for check up once a week 
for six weeks  and then once in three months for one year and once in six months for the 
second year.  At three months after the treatment the lung test will be done to assess any 
radiation induced changes in lung.  
 
Can I withdraw from this study after it starts? 
 Your participation in the study is voluntary and you are free to withdraw from the study 
anytime. If you withdraw also, you will continue to receive further standard treatment. In 
case you decide to withdraw from the study you have to inform the doctor so that he can 
advise you regarding what other treatment can be continued for you.  
 
What side effects should be expected? 
You may develop side effects while on treatment or after completion of treatment. 
Everyone taking part in the study will be carefully watched for side effects. Side effects 
can be mild to moderate. You will be given appropriate medications and if required 
radiation treatment may be stopped for few days. 
 
Likely side effects are 
Reddening of skin over the chest. 
Darkening of skin over the chest. 
Generalized weakness and fatigue. 
Peeling of superficial skin. 
Mild pain at the irradiated area which requires simple pain killers. 
Rare side effects are(occur in 3 % of patients): 
Cough 
Breathlesness 
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Inflammation of heart muscle. 
Rib fracture  
Slight increase in risk of heart disease for patients with left sided breast cancer. 
Small chance of another cancer developing several years after the treatment.  
 
What will happen if I develop any study related injury? 
We will take maximum care to avoid any study related injury. In case you develop any 
study related injury, you will be treated at no cost. However there is no scope for 
financial compensation in case of study related injury occurs. 
 
Can I become pregnant while in this study? 
Pregnancy is to be avoided while on radiation therapy, be it while being in the study or 
otherwise. If you are in the reproductive age group it is advisable to use effective 
contraception.  
 
What are the benefits of being in this study? 
By being in this study, you have a chance to complete your treatment earlier.  If this 
shorter treatment is found to be feasible, it will be very convenient for future cancer 
patients as it saves time and money.  
 
Will you have to pay for the tests and treatment? 
Yes, you will have to bear the cost of routine tests and treatment. One or two tests which 
are not routinely done, but,  done as a part of this study will be done free of cost. The 
details of payment can be discussed with your doctor in detail.  
 
What happens when the study is over? 
Once the study is over, you will further receive the rest of your treatment- chemotherapy 
or hormonal therapy according to the individual disease status. After radiation therapy, 
you will be closely observed with weekly clinical examination for six weeks. If radiation 
therapy is the last part the entire cancer treatment for you, then you will be called for 
check up after six weeks, and three months, and once in three months for an year. You 
can come for check up earlier in case you develop any new symptoms.  
 
Will my personal information be kept confidential? 
The result of this study may be published, but your personal identification  details will 
not be revealed in any publication or presentation. However, your medical records may 
be reviewed by the people associated with the study, without your additional pemission, 
even if you withdraw from the study. 
If you have any further questions please feel free to ask Dr.Balu George or Dr 
Selvamani B . 
 
 
 
 
98 
 
III 
CONSENT FORM 
Study title: Prospective single arm study to assess the feasibility and tolerability of 
hypofractionated postmastectomy radiotherapy in patients with carcinoma breast. 
 
Participant’s name: 
Date of birth/age in years: 
 
I _______________________________, daughter / wife of _________________________ 
declare that I have read the information sheet provided to me regarding this study and have 
clarified my doubts regarding this ( ). 
I also understand that my participation in this study is entirely voluntary and that I am free to 
withdraw from this study at any time without affecting my usual treatment or my legal rights ( ). 
I also understand that, I have to pay for my treatment ( ). 
I understand that I will receive free treatment for any study related injury or adverse event, but I 
will not receive any financial compensation ( ). 
I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my health records even if I withdraw from the study. I agree to this access ( 
). 
I understand that my identity will not be revealed in any information released to third parties or 
published ( ). 
I voluntarily agree to take part in this study ( ). 
 
Name: 
Signature: 
Date: 
 
Name of the witness: 
Relation to participant:  
Date: 
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IV 
                                  DATA COLLECTION FORM 
HOSPITAL NO: 
CASE NO: 
1. Age: 
2. Height: 
3. Weight: 
4. BMI: 
5. Pre/Post menopausal : 
6. Performance status: 
7. Comorbidities 
8. Laterality: 
9.  Clinical stage: 
10. Date of 1
st
 biopsy/FNAC: 
11. Neoadjuvant chemotherapy: Yes / No 
12. If Yes: Regimen: 
13. Date of last cycle: 
14. Date of surgery: 
15. MRM/SM ,ANC 
16. Pathological stage: 
17. Margin status: 
18. Hormone receptor status :ER: 
19. Hormone receptor status: PR: 
20. Her 2 neu 
21. Grade: 
22. Currently on endocrine therapy? 
23. If yes: Tamoxifen  / AI 
24. Regions planned for irradiation: 
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VI 
DVH PROFORMA 
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VII 
 
1 Column2  Column4 Column5 Column6 Column7 Column8 
S.NO H No:  Age Ht Wt BMI Menop 
1 258367F  52 157 51 20.7 2 
2 277009F  25 156 60 24.7 1 
3 066598b  65 151 68 29.8 2 
4 603308F  45 158 90 36.1 1 
5 092524C  65 150 60 25.6 2 
6 328555F  52 151 67 24.7 2 
7 433413F  47 151 61.5 27 1 
8 443544F  51 156 71 29.2 1 
9 375026F  55 147 50 23.1 2 
10 432933F  55 150 55 24.4 1 
11 311522F  40 150 67 29.8 1 
12 348507F  48 151 80.2 35.2 1 
        
 
 
 
 
Column9 Column10 Column11 Column12 Column13 Column14 Column15 Column16 
Perform Comorb Laterality T N NACT_Surgery NACT_if_yes Date_last_cycle 
1 0 2 2 0 1 1 30.6.13 
1 0 1 4 2 1 3 5.1.13 
1 6 1 3 1 1 4  
1 2 1   2   
1 1,2,5 2 2 0 2  14.3.13 
1 2,4 1 3 1 1 3 28.3.13 
1 0 1 2 0 2   
1 0 2 3 1 1 1 3.7.13 
1 0 1 3 1 1 1 7.3.13 
1 1,2 1 3 1 1 3 24.7.13 
1 1 2 2 0 2   
1 2 2 3 2 1 1  
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Column17 Column18 Column19 Column20 Column21 Column22 Column23 Column24 
Date_surgery p_T p_N ER PR her_2 adj_chemo adj_chemo_if 
yes 
6.8.13 1 0 0 0 0 1 2 
13.11.12 2 1 0 0 0 1 3 
22.11.13 2 0 1 1 0 0  
15.5.13   1 0 0 1 1 
3.12.12 3 0 1 1 1 1 1 
29.113 0 0 0 0 0 1 3 
1.4.13 2 0 1 1 0 1 1 
23.7.13 1 0 0 0 0 1 2 
17.4.13 1 0 1 0 1 1 2 
28.5.13 1 1 1 1 0 1 3 
24.8.12 2 0 1 1 0 1 1 
12.2.13 2 2 1 1 0 1 2 
 
Column25 Column26 Column27 Column28 Column29 Column30 Column31 Column32 
Horm 
therapy 
Horm_if_yes_ Regions Treated  CTV_G_Mx CTV_V90 CTV_V95 
  1 CW RIGHT 106 95.54 91.55 
  2 CW,SC LEFT 104 97.38 87.98 
1 2 1 CW LEFT 108 99.04 96.02 
0  1 CW LEFT 107 99.37 95.23 
1 2 1 CW RIGHT 104 94.05 86.33 
  1 CW LEFT 107 98.63 95.66 
1 1 1 CW LEFT 106 98.17 92.06 
  2 CW,SC RIGHT 106 98.8 96.8 
0  2 CW,SC LEFT 107 96.4 91.6 
0  2 CW,SC LEFT 106 98.1 94.2 
0   CW RIGHT 106 98.34 92.52 
1 1 2 CW,SC RIGHT 104 97 91.1 
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Column33 Column34 Column35 Column36 Column37 Column38 Column39 Column40 
CTV_V100 CTV_V105 CTV_V107 CTV_D98 CTV_D2 V12_IPSI_LNG V10_IPS_LNG V20_IPS_LNG 
53.2 3.43 0 78 105 20.2 20.99 18.12 
28.18 0 0 89 103 20.85 21.61 18.36 
71 5.5 0.78 93 106 19.42 20.06 17.43 
47.99 4.3 0.49 93 106 14.19 14.99 11.75 
4.3 0 0 71 104 18.18 19.06 15.51 
60.44 8.45 0.41 92 106 14.93 15.62 12.91 
45.07 2.88 0 90 105 7.43 7.94 5.83 
58.5 0.9 0 92 104 21.1 22.4 17.3 
69.1 3.1 0 85 105 35 37.6 32.1 
71.8 9 0.2 90 105 29.5 30.8 25.7 
47 1.96 0.14 88 105 16.23 16.96 13.97 
60.6 5.1 0.5 80 106 25.2 26.1 21.5 
 
Column42 Column43 Column44 Column45 Column46 Column47 Column48 Column49 
CNTRA_LNGV10 CNTRA_LNGV20 COMB_LNGV10 COMB_LNGV20 HEART_V10 HEART_V2 HEART_V33 C.BREAST_MEAN_DOSE 
0 0 11.16 9.65 0 2.8 0 67.7 
0 0 9.63 8.1 14.26 42.86 7.21 67.7 
0 0 9.2 7.8 9.27 31.07 5.3 40 
0 0 7.08 5.49 3.62 21.53 1 58.9 
0 0 19.06 15.5 0 2.6 0 72.5 
0 0 6.58 5.45 8.31 27.66 3.33 64.4 
0 0 2.76 2.02 14.15 44.07 6.09  
0 0 13.3 10.3 0 4.2 0 50 
0 0 16.1 13.9 21.4 56.2 9.3 74 
0 0 13.4 11.5 12.7 35.7 4.5 58 
0 0 8.56 6.84 0.11 14.22 0 126.5 
0 0 16 13 0 2.1 0 38 
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C.BREAST_D2 C.BREAST_MX_D GAP_CHEMO_RT RT_START RT_END OTT RT_FATIGUE1 RT_FATIGUE2 
2.8 3.76 36 18.11.13 5.12.13 18 0 0 
3.2 7.95 22 28.1.13 20.2.13 24 0 0 
1.9 3.36  3.6.13 21.6.13 19 0 0 
3.7 19.96 28 6.11.13 29.11.13 24 0 0 
4.1 13.4 33 17.4.13 7.5.13 21 0 0 
3.2 8.44 33 1.5.13 23.5.13 23 0 1 
  30 20.8.13 9.9.13 21 0 0 
2.78 11.7 37 18.11.13 6.12.13 19 0 1 
6.46 33.68 47 29.8.13 18.9.13 21 0 1 
2.96 25.1 22 16.8.13 5.9.13 19 0 1 
11.3 34.63 68 4.4.13 24.4.13 21 1 1 
2.18 37.22 33 5.6.13 26.6.13 20 0 0 
 
F_DERM4 F_DERM5 F_DERM6 F_DERM7 F_DERM8 F_DERM9 PFT 
DUE 
DONE/NOT FEV1 PRE 
RT 
s Ejection 
fraction 
fvc pre fvc post 
      0 0   56.9   
2   1  1 1 1 90.5 80.4 60.9 2.92 2.52 
1  1  1  1 0  78    
      0 0   56.2   
      1 0   57.5   
1 1  1  1 1 1 60.4 75 58.2 1.61 1.69 
 0  0  0 0 0   57.2   
      0 0   56.9   
 1  0  0 0 0   57.8   
      0 0   56   
3 1 1 1  1 1 1 59.1 53.3 56 1.79 1.76 
      1 0      
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